Anthony Fauci Discusses Research Approaches to Sustaining HIV Remission Without Antiretroviral Therapy
Fauci spoke to TheBodyPRO at this year's International AIDS Conference on approaches to HIV remission and durable control of HIV without antiretroviral therapy.
Once viable long-acting HIV prevention and treatment options have reached the market, what will be their true impact? Leading HIV clinician-researcher Anton Pozniak, M.D., shares his expertise.
Why do we lack a cure for HIV infection, and what research is underway to help achieve that goal? A new video from NIAID provides answers.
Three researchers talk about ongoing HIV cure research within the AIDS Clinical Trials Group, treatment interruptions, and when we might see a cure.
On June 6, 2018, without news from the U.S. FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.
NIH Clinical Trial to Track Outcomes of Kidney Transplantation From HIV-Positive Donors to HIV-Positive Recipients
The first large-scale clinical trial to study kidney transplantations between people with HIV has begun at clinical centers across the U.S.
New strategies are here, more are on the way, and the future of ART remains bright, according to W. David Hardy, M.D.
Even a moderately efficacious HIV vaccine could make a significant additional contribution to halting the virus. And for HIV-positive people, a true end to HIV lies not in an epidemiological calculus, but in a cure.
The antiretrovial therapy pipeline includes new medications in existing drug classes as well as medications with novel mechanisms of action.
The ability of elite controllers to maintain undetectable viral loads and relatively preserved CD4 T-cell counts in the absence of antiretroviral therapy has led them to be proposed as a model for a functional cure of HIV infection.